Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 7Phase 1 6Phase 1/2 4Phase EARLY_PHASE1 2

Status

Active not recruiting 7Recruiting 5Completed 3Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Tumor-Agnostic 1Breast 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Metastatic Castration-sensitive Prostate Cancer 1Breast Neoplasms 1

Interventions

Carboplatin 108Cisplatin 98Paclitaxel 79pembrolizumab 70Gemcitabine 60Pemetrexed 49Cyclophosphamide 48Dexamethasone 47Docetaxel 46durvalumab 44Capecitabine 44Radiotherapy 42Doxorubicin 40Lenalidomide 38Specimen Handling 37Nivolumab 37Oxaliplatin 35Rituximab 34Magnetic Resonance Spectroscopy 33Fluorouracil 33Etoposide 32Bevacizumab 32Vincristine 30atezolizumab 29Radiation 28Leucovorin 28Bortezomib 26Prednisone 23Letrozole 23Fulvestrant 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × niraparib × Clear all
NCT04497844 2026-05-11

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Tesaro, Inc.

Phase 3 Active not recruiting
733 enrolled 21 charts 1 FDA
Gynecologic

Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting
1,400 enrolled 18 charts
Gynecologic

Ovarian Neoplasms

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting
785 enrolled 2 FDA

Neoplasms, Recurrence

NCT04915755 2025-07-16

ZEST

GlaxoSmithKline

Phase 3 Active not recruiting
40 enrolled 13 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡